Skip to main content
. 2019 Oct 24;250(1):19–29. doi: 10.1002/path.5344

Figure 3.

PATH-5344-FIG-0003-c

PFS and OS in patients treated with ICI therapy increased in patients with high TMB. (A) PFS from start of immunotherapy in patients with high (≥ 9 Mut/Mb) versus low/intermediate (orange line, < 9 Mut/Mb) TMB [median 16.4 versus 2.6 months, Mantel–Haenszel hazard ratio 0.42 (95% CI 0.25–0.72), log‐rank Mantel–Cox test p = 0.0014]. (B) OS from start of immunotherapy in patients with high versus low/intermediate TMB [median 37.5 versus 9.0 months, Mantel–Haenszel hazard ratio 0.51 (95% CI 0.29–0.90), log‐rank Mantel–Cox test, p = 0.0197]. Patients at risk according to the time point written on the x‐axis of each graph are shown below each plot.